Johnson & Johnson Appoints Michael Bodner as New Head of Electrophysiology and Neurovascular Group to Revitalize Struggling Businesses

Overseas Reports:Johnson & Johnson Appoints Biosense Webster beforePresidentMichael Bodner forNew Chairman of Electrophysiology and Neurointervention Group.

Michael Bodner is a veteran of Johnson & Johnson, who joined the company in 2017 (Biosense Webster) holdsVice President of Sales, USA. Four years later, promoted toPresident of Biosense Webster Global, while serving asDuring the tenure of the Global President of Biosense WebsterAbiomed Acquisition and Subsequent Integration. Starting from 2023, serving Johnson & JohnsonGlobal Head of Heart Recovery, Johnson & Johnson, 2024Chairman of Cardiac Recovery and Circulation Repair Group.

Cardiac Recovery and Circulation Repair Group mainly covers Johnson & Johnson's large acquisitions in recent years, such asAbiomed、Shockwave、V-Wave. CurrentlyCardiac recovery and circulatory repair businesses can be said to have no rivals globally, presenting a scene of prosperity.

Johnson & JohnsonElectrophysiology and neurointervention are currently encountering some difficulties. Last month, Johnson & JohnsonNeurointervention (Cerenovus) was reported to be up for sale, and the market is buzzing with the news of a potential sale.This business means that this business development is definitely not as expected. In facing numerous neurointervention competitors,Cerenovus' performance was unremarkable. This is also why the market hopes Johnson & Johnson will divest.Cerenovus Reasons.

Johnson & JohnsonIn the PFA era, Johnson & Johnson's electrophysiology business has clearly failed to keep up in a timely manner, lagging behind Boston Scientific and Medtronic, resulting in the current passive situation. What made the executives of Johnson & Johnson even more dissatisfied was the safety issue with its first PFA product that surfaced earlier this year. However, this problem was caused by the operator not strictly following the instructions.It was caused by the execution of Ming Shu, but this...Johnson & Johnson's reputation has been significantly impacted. Therefore, Johnson & Johnson executives...EP VeteranMichael Bodner Returns, RestructuresElectrophysiology and Neurointervention Business, LetElectrophysiology and Neurointervention Return to the Peak.

Michael Bodner's Evaluation

"I am proud to rejoin the Johnson & Johnson team where my career began — helping to drive the rapid growth of our cardiovascular product portfolio. This work requires us to rethinkFocus on the most important core: the patient. Every decision we make and every innovation we pursue must start and end with the patient. Great achievements do not happen by chance; they emerge from the cultural soil we carefully cultivate — where people can build strong partnerships, inspire each other to strive for excellence, and create collaborative spaces that foster innovation. Returning to this family is exciting, and I am full of anticipation for the future. Now, let’s give it our all!